A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)

• Status: Recruiting
• Trial end date: 2024-05-13

Summary

The purpose of the study is to evaluate the efficacy of bedaquiline (BDQ) compared with rifamycin when administered as part of a treatment regimen with clarithromycin (CAM) and ethambutol (EB) in adult participants with treatment-refractory Mycobacterium avium complex-lung disease (MAC-LD) at Week 24 for microbiological assessment in mycobacteria growth indicator tube (MGIT).

• Phase: Phase 2/Phase 3

Details

• Lead Sponsor: Janssen Pharmaceutical K.K.
• Treatments: Bedaquiline; Clarithromycin; Ethambutol; Rifabutin; Rifampin